Across TCGA pan-cancer cohorts, CDK4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CDK4 data layer compared with 27 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher CDK4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CDK4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
SKCM, KIRP, and UCEC are the cancer types where CDK4 Mutation most reproducibly stratifies survival.